PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24942275-10	2014	FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors.	FOLFIRI regimen	0-7	KRAS proto-oncogene, GTPase	Homo sapiens	141-145	
24942275-10	2014	FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors.	FOLFIRI regimen	0-7	NRAS proto-oncogene, GTPase	Homo sapiens	150-154